» Articles » PMID: 22008817

Antigenic Mimicry-mediated Anti-prion Effects Induced by Bacterial Enzyme Succinylarginine Dihydrolase in Mice

Overview
Journal Vaccine
Date 2011 Oct 20
PMID 22008817
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Prions, the causative agents of prion diseases, are immunologically tolerated because their major component, prion protein (PrP), is a host-encoded molecule. Therefore, no effective prion vaccines have been developed. We previously showed that heterologous bovine and sheep PrP immunizations of mice overcame tolerance by an antigenic mimicry mechanism to efficiently induce anti-PrP auto-antibodies (Abs), significantly prolonging incubation times in mice subsequently infected with the mouse-adapted Fukuoka-1 prion. These results prompted us to investigate if non-mammal derived molecules able to antigenically mimic anti-prion epitopes, could act as prion vaccines. We show here that immunization of mice with recombinant succinylarginine dihydrolase, a bacterial enzyme with a peptide sequence similar to an anti-prion epitope, induced anti-PrP auto-Abs with anti-prion activity and significantly retarded survival times of the mice subsequently infected with Fukuoka-1 prions. These results might open a way for development of a new type of antigenic mimicry-based prion vaccine.

Citing Articles

Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.

Mukherjee A, Biswas S, Roy I Acta Pharmacol Sin. 2025; .

PMID: 39890942 DOI: 10.1038/s41401-024-01455-w.


Vaccines for prion diseases: a realistic goal?.

Napper S, Schatzl H Cell Tissue Res. 2023; 392(1):367-392.

PMID: 36764940 PMC: 9918406. DOI: 10.1007/s00441-023-03749-7.


Immunization with Genetically Modified Trypanosomes Provides Protection against Transmissible Spongiform Encephalopathies.

Triller G, Garyfallos D, Papavasiliou F, Sklaviadis T, Stavropoulos P, Xanthopoulos K Int J Mol Sci. 2022; 23(18).

PMID: 36142526 PMC: 9503410. DOI: 10.3390/ijms231810629.


Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.

Ishibashi D, Ishikawa T, Mizuta S, Tange H, Nakagaki T, Hamada T Neurotherapeutics. 2020; 17(4):1836-1849.

PMID: 32767031 PMC: 7851219. DOI: 10.1007/s13311-020-00903-9.


Immunotherapy against Prion Disease.

Ma Y, Ma J Pathogens. 2020; 9(3).

PMID: 32183309 PMC: 7157205. DOI: 10.3390/pathogens9030216.